[18F]PI-2620 Phase 3 Histopathological Study

Summary

This study is an open-label, multi-center, non-randomized pivotal Phase 3 study to assess the efficacy and safety of PET imaging with [18F]PI-2620 for detection of tau deposition in subjects with Alzheimer's disease (AD) and controls during lifetime when compared to histopathology obtained after death and completion of brain autopsy.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Alzheimer Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

50 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Lantheus Biosciences Ltd.

Last updated on ClinicalTrials.gov

May 22, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites